Subcommittee on Precision Medicine
Matthew J. Walter, MD ('23)
Akiko Shimamura, MD ('23)
Pamela S. Becker, MD, PhD ('25)
John C. Byrd, MD ('25)
Jorge Di Paola, MD ('23)
Ann-Kathrin Eisfeld, MD ('24)
Lucy Godley, MD, PhD ('23)
Caroline A. Heckman, PhD ('24)
Annette S. Kim, MD, PhD ('24)
Jatinder K. Lamba, PhD ('25)
Charles G. Mullighan, MD ('24)
Elli Papaemmanuil, PhD ('25)
Steven Z. Pavletic, MD, PhD ('25)
Daniel Aaron Pollyea, MD ('25)
Andrew W. Roberts, MBBS, PhD ('24)
David Peter Steensma, MD ('23)
Peter Valk, PhD ('23)
Arun Wiita, MD, PhD ('25)
Faith Davies, MD ('24) -
Jonathan Gerber, MD ('24) -
Kelly Rose, PhD
The increased use of genome sequencing and genomic profiling in research and the clinical settings has significantly improved the diagnoses and treatment of hematologic diseases by identifying unique genomic variations. Investigation of these variations, in combination with alterations in the proteome and metabolome, can identify contributors to disease and vulnerabilities to target therapeutically. ASH has an ongoing interest in enhancing precision medicine and the application of Omics profiling of malignant and classical hematological conditions.
The Subcommittee on Precision Medicine, a subcommittee of the Committee on Scientific Affairs, aims to improve the use of genomic, proteomic, and metabolomic data in clinical care, research, and education. The subcommittee aims to develop strategies to improve and disseminate:
- The utility of bioinformatics and cloud-based tools for the interpretation of germline and somatic variants during the process of genetic testing, including from racial and ethnic minority groups.
- The applicability of germline and somatic variant testing and advocate for its access and reimbursement.
- The importance of standardized collection of clinical data with Omics profiling.
- The utility of functional significance of germline and somatic genomic variation.
- The use of Omics data for disease prevention, guiding treatment decisions, and monitoring disease progression and/or measurable residual disease.
- Pharmacogenomics in hematology.
- Incorporation of new technologies and large public genome data sets for precision medicine.
The chair and vice chair of the Subcommittee on Precision Medicine each serve one-year terms with the immediate past chair serving another one-year term on the subcommittee as a member. If not already a member of the Committee on Scientific Affairs, the Chair of the Subcommittee on Precision Medicine serves as a liaison to the Committee on Scientific Affairs.
Members of the Subcommittee on Precision Medicine are appointed to three-year staggered terms (with the possibility of renewal once) and include experts focused on both malignant and classical hematology. The membership includes liaison members from the Committee on Educational Affairs and the Committee on Practice.
Members of the Subcommittee on Precision Medicine are required to participate in regularly scheduled conference calls and possibly one in-person meeting if deemed necessary.